Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
Tanguy Y. Seiwert(Georgetown University), Laura Q.M. Chow(The University of Texas at Austin), Dung T. Le(Johns Hopkins University), Shilpa Gupta(Cleveland Clinic), Barbara Burtness(Yale University), Ranee Mehra(University of Maryland, Baltimore), Karl Heath(Merck & Co., Inc., Rahway, NJ, USA (United States)), Raanan Berger(Tel Aviv University), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Se‐Hoon Lee(Samsung Medical Center), Robert I. Haddad(Georgetown University), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amy E. Blum(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Princeton University), Makoto Tahara(National Cancer Center Hospital East)
Cited by 103
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k